- In May 22, 2025, MTF Biologics and Kolosis BIO jointly launched two novel allografts—ATLAS Sternal Repair Matrix and IKON—aimed at improving sternal fusion and soft tissue repair in cardiac surgery. These products offer advanced matrix proteins and growth-factor support to enhance healing in high-risk patient populations
- In March 27, 2025 AlloSource achieved its 200th implantation of AceConnex Pre‑Sutured Fascia, the only 510(k)-cleared fascia allograft pre‑sutured for hip labral reconstruction. Surgeons report improved consistency and significant time savings in operative procedures
- In March 26, 2025 MTF Biologics completed the first patient implantation for its FlexHD® Pliable device in an IDE clinical trial (SHAPE), aimed at pre-pectoral breast reconstruction. This milestone marks the first IDE-approved human acellular dermal matrix for this surgical application
- In January 2025 MTF Biologics awarded its 2024 Innovation in Allograft Translational Research Grants, totaling USD60 million since 1987. These grants support tissue repair and reconstructive surgery, illustrating long-term commitment to R&D in soft tissue allografting
- In May 2023 AlloSource introduced AlloMend Duo Acellular Dermal Matrix, offering one of the largest footprints in its line for soft tissue reconstruction. Earlier in March 2023, they reported positive clinical outcomes for ProChondrix CR in focal cartilage defect repair
